Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition and Cardiology, 33000 Bordeaux, France.
Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition and Cardiology, 33000 Bordeaux, France.
Diabetes Metab. 2024 Mar;50(2):101524. doi: 10.1016/j.diabet.2024.101524. Epub 2024 Feb 11.
Cardiovascular disease is frequent in type 2 diabetes mellitus (T2DM). We investigated the relationship between skin autofluorescence (SAF) of advanced glycation end-products and later cardiovascular events (CVEs) in patients with T2DM.
We conducted a retrospective analysis of 504 patients hospitalized for uncontrolled and/or complicated T2DM between 2009 and 2017. SAF was measured using an AGE-Reader. Participants were followed up from admission to December 2020, for the onset of a CVE (myocardial infarction, stroke, revascularization procedures or cardiovascular death). The relationship between SAF and CVE was analyzed by multivariable Cox regression. Log-rank curves were used to compare CVE-free survival in patients whose SAF at admission was above versus below the whole-population median. The analysis was repeated in subjects without/with macroangiopathy (defined as myocardial infarction, stroke, peripheral revascularization) at baseline.
During 54 months of follow-up, 69 (13.7%) patients had a CVE. Baseline SAF was significantly higher in patients with T2DM who later experienced a CVE (2.89 ± 0.70 arbitrary units versus 2.64 ± 0.62 in others, P = 0.002). This relationship was significant after adjusting for age, sex, conventional risk factors (diabetes duration, HbA1c, arterial hypertension, dyslipidemia, smoking, body mass index), vascular complications, C-reactive protein, and treatments for diabetes. The CVE-free survival curves differed between subjects whose SAF was above the whole-population median (log-rank: P = 0.002) and those whose SAF was above the macroangiopathy-free sub-population median (log-rank: P = 0.016).
SAF of advanced glycation end-products was related to a higher incidence of later CVE in patients with T2DM.
心血管疾病在 2 型糖尿病（T2DM）中较为常见。我们研究了晚期糖基化终产物皮肤荧光（SAF）与 T2DM 患者后期心血管事件（CVE）之间的关系。
我们对 2009 年至 2017 年期间因控制不佳和/或合并 T2DM 住院的 504 例患者进行了回顾性分析。使用 AGE-Reader 测量 SAF。从入院开始对参与者进行随访，随访时间截至 2020 年 12 月，以确定是否发生 CVE（心肌梗死、中风、血运重建或心血管死亡）。使用多变量 Cox 回归分析 SAF 与 CVE 之间的关系。对数秩曲线用于比较入院时 SAF 高于或低于全人群中位数的患者的 CVE 无事件生存率。在基线时无/有大血管病变（定义为心肌梗死、中风、外周血运重建）的患者中重复该分析。
在 54 个月的随访期间，69 例（13.7%）患者发生了 CVE。与未发生 CVE 的患者相比，发生 CVE 的 T2DM 患者的基线 SAF 显著升高（2.89 ± 0.70 任意单位与 2.64 ± 0.62，P = 0.002）。在校正年龄、性别、常规危险因素（糖尿病病程、HbA1c、动脉高血压、血脂异常、吸烟、体重指数）、血管并发症、C 反应蛋白和糖尿病治疗后，这种关系仍然显著。SAF 高于全人群中位数的患者（对数秩：P = 0.002）和 SAF 高于大血管病变无事件亚人群中位数的患者（对数秩：P = 0.016）的 CVE 无事件生存曲线存在差异。
晚期糖基化终产物的 SAF 与 T2DM 患者后期 CVE 的发生率升高相关。
